CLEARSIDE BIOMEDICAL, INC. (NASDAQ:CLSD) Files An 8-K Regulation FD DisclosureItem 7.01
On April23, 2018, members of management of Clearside Biomedical, Inc. (the “Company”) will hold meetings to review, among other things, the Company’s product candidate pipeline and recent clinical results. The presentation that will be used in the meetings contains certain new charts of clinical data from the Company’s pivotal Phase 3 clinical trial of suprachoroidal CLS-TA in patients with macular edema associated with non-infectious uveitis, which charts are furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
| Item 7.01 | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. |
Description |
| 99.1 | Clinical Data Charts. |
Clearside Biomedical, Inc. ExhibitEX-99.1 2 d576174dex991.htm EX-99.1 EX-99.1 Percent Subjects Resolution of Signs of Uveitis % Subjects Displaying Change to Zero at Week 24 There was at least a 50% difference in each of these measures Anterior Chamber Cells Anterior Chamber Flare Vitreous Haze Active Control Active Control Active Control Exhibit 99.1 Patient Rescue: Kaplan-Meier 85-90% of subjects in the CLS-TA arm were not rescued,…To view the full exhibit click here
About CLEARSIDE BIOMEDICAL, INC. (NASDAQ:CLSD)
Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment. With its microinjector, drugs are injected into and spread within and through the suprachoroidal space, (SCS), which is the space located between the choroid and the outer protective layer of the eye known as the sclera. With the suprachoroidal injection, its product candidates are more directly administered to the retina and choroid as compared to other ocular drug administration techniques, such as injections of drug into the vitreous, a jelly-like substance that occupies the central portion of the eye.
